juan shou yu
wang jun zhi ; shen xin liang ;

..............page:2279

Dulaglutide: a new drug for the treatment of type 2 diabetes
DONG Xian-hong;ZHU Jiang;MA Shuai;Guangming Hospital of Traditional Chinese Medicine;State Key Laboratory of New Drug & Pharmaceutical Process;Shanghai Institute of Pharmaceutical Industry;China State Institute of Pharmaceutical Industry;

..............page:2281-2283+2311

Siltuximab: a novel IL-6 monoclone antibody drug for the treatment of muticentric castleman disease
ZHANG Yu-qin;DU Xiao-li;Department of Pharmacy;Peking Union Medical College Hospital;Chinese Academy of Medical Science;

..............page:2284-2287+2329

Analysis of the situation of clinical trials for antitumor drugs supported by foreign pharmaceutical industries in China
CHENG Xian-kui;WU Zhi-ang;School of Business Administration;Shenyang Pharmaceutical University;

..............page:2288-2294+2323

Research on the patent operation of transnational corporations based on vaccines for cervical cancer Gardasil and Cervarix
WANG Jing;WEI Jun;FENG Xiao-liang;WANG Chao;WEI Wei;Patent Examination Cooperation Center of the Patent Office;SIPO;

..............page:2295-2300

Application scope of drug test data protection under TRIPS and the legislative choice of China
YANG Li;ZHANG Da-wei;CHEN Jing;LIN Lin;College of Business Administration;Shenyang Pharmaceutical University;

..............page:2301-2307+2335

Introduction of the drafting procedure of “Guidelines on Development and Evaluation of Biosimilars(drafting) ”
BAI Yu;WANG Hai-xue;XIE Song-mei;GAO Chen-yan;YIN Hong-zhang;LUO Jian-hui;Centre for Drug Evaluation;State Food and Drug Administration;

..............page:2308-2311

Analysis of N-linked glycan profile of human/murine chimeric anti-CD20 antibodies by capillary electrophoresis
WANG Wen-bo;WANG Lan;WANG Xin;YU Chuan-fei;ZHANG Feng;LIU Chun-yu;CHEN Wei;LI Meng;GAO Kai;Department of Monoclonal Antibody Products of National Institutes for Food and Drug Control;Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products;

..............page:2312-2316+2345

Optimization and application of HUVEC proliferation inhibitory assay
ZHANG Feng;XU Gang-ling;YU Chuan-fei;WANG Wen-bo;CHEN Wei;LIU Chun-yu;WANG Lan;GAO Kai;Division of Monoclonal antibody Products;National Institutes for Food and Drug Control;

..............page:2317-2323

Recent progress in researches for action mechanism of adjuvants
LIU Yi-bo;GENG Xing-chao;WANG Ju-feng;LI Bo;Key Laboratory of Beijing for Nonclinical Safety Evaluation of Drugs;National Center for Safety Evaluation of Drugs;National Institute for Food and Drug Control;

..............page:2324-2329

Preclinical safety similarity evaluation of IBI305 and Avastin
LI Wei;LI Jia;SUN Li;MIAO Yu-fa;QU Zhe;DAN Mo;WANG Ju-feng;WANG Chun-ming;LI Bo;National Institutes for Food and Drug Control;Innovent Biologics Limited;

..............page:2330-2335

Determination of drug-antibody ratio in a cysteine conjugation based antibody-drug conjugate
YU Chuan-fei;WANG Wen-bo;ZHANG Feng;LIU Chun-yu;LI Meng;CHEN Wei;GUO Sha;WANG Lan;GAO Kai;WANG Jun-zhi;Division of Monoclonal antibody Products;National Institutes for Food and Drug Control;Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products;

..............page:2336-2340

zhong guo xin yao za zhi ru xuan xin wen chu ban guang dian zong ju 2015 nian bai qiang bao kan

..............page:2340

Key points for operational steps of vaccine clinical trials
MO Zhao-jun;HUANG Teng;LIANG Xin-yuan;Guangxi Centre for Disease Prevention and Control;

..............page:2341-2345

Establishment and application of a single immunodiffusion method for determining concentration of recombinant Pseudomonas aeruginosa exotoxin A
LI Yan-ting;FAN Feng-feng;FENG Yi-yang;JIN Xin;WU Zhao-jin;ZHAO Zhi-qiang;XIE Gui-lin;TAN Xiao-mei;Lanzhou Institute of Biological Products Co.;Ltd.;

..............page:2346-2351

zhong guo xin yao za zhi guan fang wei bo he wei xin yao nin guan zhu

..............page:2351

Chinese Pharmacopoeia 2015 and the development of bio-pharmaceutical industry in China
GUO Zhong-ping;Chinese Pharmacopoeia Commission;

..............page:2352-2356

Recent progress in researches for biomarkers of immunotoxicity
GENG Xing-chao;PU Jiang;LI Bo;WANG Jun-zhi;Beijing Key Laboratory;National Center for Safety Evaluation of Drugs;National Institute for Food and Drug Control;

..............page:2357-2362

Impact factors in the process development for therapeutic antibodies
ZHU Xiang-yang;Huabo Biopharma and Huaota Biopharma;Members of Zhejiang Huahai Pharmaceutical;

..............page:2363-2368

Current progress in the development of human papillomavirus vaccine
CHEN Wei-feng;WU Kun-bao;LIAN Zhi-guo;LIU Yu;WU Yan-zhuo;XU Ming-bo;College of Life Science and Technology;China Pharmaceutical University;Beijing SL Pharmaceutical Co.;Ltd.;

..............page:2369-2375+2400

Advance in development of the drugs targeting EGFR for cancer therapy
ZHU Hai-you;HU Chang-hua;College of Pharmaceutical Sciences of Southwest University;Chongqing Pharmaceutical Process Engineering and Quality Control Center;

..............page:2376-2382

Long-term efficacy and safety of tocilizumab in patients with rheumatoid arthritis: an analysis of at least 6 months exposure
FENG Xiao-xue;ZHU Shang-ling;CAO Shuang-yan;LIU Fang;GU Jie-ruo;HUANG Jian-lin;Department of Rheumatology;Third Affiliated Hospital of Sun Yat-sen University;

..............page:2383-2387

Research and evaluation on biological activities of anti-Her2 antibody A and innovative drug
DING Ding;LIANG Jin-feng;MIAO Shi-wei;WANG Yan;WANG Hai-bin;Hisun Pharma Co.;Ltd.;Zhejiang Center for Drug and Cosmetic Evaluation;Zhejiang Hisun Pharmaceutical Co.;Ltd.;

..............page:2388-2394

Characterization of trisulfide modification for candidate drug of antibody
LI Wen-hua;ZHOU Dong-mei;XU Jun;SUEN Wen-zheng;YANG Bin;Sunshine Lake Pharma Co.;Ltd.;

..............page:2395-2400